Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2019 16:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
August 14, 2019 17:11 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

LOS ANGELES, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
July 31, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
July 11, 2019 17:28 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...
July 02, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
May 30, 2019 07:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
March 29, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update

LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
March 05, 2019 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
February 12, 2019 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- ...
January 23, 2019 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019

LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...

Next Page keyboard_arrow_right